Synthesis of Optically Active Aryloxypropanolamines and Arylethanolamines

Total Page:16

File Type:pdf, Size:1020Kb

Synthesis of Optically Active Aryloxypropanolamines and Arylethanolamines Europaisches Patentamt European Patent Office 00 Publication number: 0 249 610 B1 Office europeen des brevets © EUROPEAN PATENT SPECIFICATION © Date of publication of patent specification: 25.08.93 © Int. CI.5: C07C 57/00, C07C 67/02, C07C 217/14, C07D 209/82, © Application number: 86907140.7 C07D 215/36, C07D 237/02, C07D 239/02, ' C07D 261/06, w© Daten * of,„■ filing:fl ing: a 14.11.86« oc C07D 265/30,, C07D 277/04 © International application number: PCT/US86/02407 © International publication number: WO 87/03584 (18.06.87 87/13) SYNTHESIS OF OPTICALLY ACTIVE ARYLOXYPROPANOLAMINES AND ARYLETHANOLAMINES. © Priority: 04.12.85 US 804407 © Proprietor: THE DU PONT MERCK PHARMA- CEUTICAL COMPANY @ Date of publication of application: Barley Mill Plaza, Building 25 23.12.87 Bulletin 87/52 Wilmington, Delaware 19880(US) © Publication of the grant of the patent: @ Inventor: MAI, Khuong, H., X. 25.08.93 Bulletin 93/34 4751 N Pulaski RD Chicago, IL 60630-431 2(US) © Designated Contracting States: Inventor: PATIL, Ghanshyam CH DE FR GB IT LI SE 340 Albert Drive Vernon Hills, IL 60061 (US) © References cited: Inventor: MATIER, William, L. US-A- 4 202 978 1214 Parliament Court Libertyville, IL 60048(US) AGRIC. BIOL. CHEM., May 1982, vol. 46, no. 5, pages 1153-1157; S. IRIUCHIJIMA et al, "Asymmetric Hydrolysis of Representative: Seaborn, George Stephen et (plus/minus)-1,2-Diacetoxy-3-chloropropane al and Its Related Compounds with Lipase. c/o Edward Evans & Co. Chancery House 00 Synthesis of Optically Pure (S)-Propranolol" 53-64 Chancery Lane London WC2A 1SD (GB) CO CM Note: Within nine months from the publication of the mention of the grant of the European patent, any person ® may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition CL shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee LU has been paid (Art. 99(1) European patent convention). Rank Xerox (UK) Business Services (3. 10/3.6/3.3. 1) EP 0 249 610 B1 Description Aryloxypropanolamines (1) and arylethanolamines (2) are widely used therapeutic agents, particularly those compounds possessing potent beta-adrenergic receptor blocking activity. Use beta-adrenergic bloc- 5 king agents are widely used for a number of cardiovascular therapeutic indications, such as hypertension, angina pectoris, cardiac arrhythmias, myocardial infarction and more recently in the treatment of glaucoma. In addition, certain aryloxypropanolamines possess potent beta-adrenergic stimulating properties and such compounds are used as cardiac stimulants. Among beta-blocker oxypropanolamines, the R isomers are less active or essentially devoid of beta- io blocking activity as compared to their counterpart S isomers. Similarly, the R-isomer beta-agonists are are potent agents than their S-isomer counterparts Ar^****^ Ar-0^sv^s^NHR or 20 Conventional methods for preparing such compounds utilize HBr/AcOH treatment of the diol 4 to provide 25 the bromoacetoxy 5. Subsequently, the bromoacetoxy 5 is transformed into an epoxide which is then treated with the corresponding amine to provide the desired beta-blocker in separate stages. Such a procedure is described by S. Iriuchijima and N. Kojima, Agric. Biol. Chem. 46 (5), 1153 (1982). The diol 4 may be prepared by hydrolysis of the ketal 3, or, as described by Iriuchijima and Kojima, by reaction of 1 ,2- diacetoxy-3-chloropropane with a phenol. In such conventional methods, to prepare the optically active 30 aryloxypropanolamines, four steps are required, starting from the ketal 3 or 1 ,2-diacetoxy-3-chloropropane. An efficient and an economical process for prepare the separate isomers is therefore highly desirable. ft-V" 35 OH QAc Ar- 40 US-A-4 202 978 discloses a process wherein a ketal is hydrolysed to the corresponding diol which is reacted with a trialkylorthoacetate to give a cyclic orthoacetate which is converted to a 1-aralkyl-3-halo- 45 propylacetate. SUMMARY OF THE INVENTION In accordance with the present invention, there is provided a method of preparing a compound of the 50 formula 55 EP 0 249 610 B1 wherein Ar is aryl, substituted aryl, heteroaryl, or aralkyl, X is chloro, bromo or iodo and Y is hydrogen, loweralkyl or cycloloweralkyl, which method comprises: reacting a selected racemic or chiral dioxolane of the formula Ar-0 or 10 wherein Ar is defined as above and Ri and R2 are each independently hydrogen loweralkyl, cycloloweral- 15 kyl, or R1 and R2 together with the carbon atom form a 3 to 6 member cycloalkyl group or aryl group, with an acid of formula HX, wherein X is defined as above, in solution in a organic acid of the formula Y-COOH wherein Y is defined as above. A racemic or chiral (i.e. optically active) aryloxypropanolamine (1) or arylethanolamine (2) may be prepared by reacting the compound prepared by the method specified in the preceding paragraph with an 20 amine or by reacting the compound with a base to prepare an epoxide and reacting the epoxide with an amine. OH NHR 25 • JL Ar^*^ Ar-O^^N^^NHR• n ^\uuO ora* Ar^^*^s^ 30 In Formula (1) and (2) R is alkyl, aryl, aralkyl or WB wherein W is a straight or branched chain alkylene of from 1 to about 6 carbon atoms and wherein B is -NR2COR3, -NR2CONR3R+, -NR2SO2R3, -NR2S02NR3R4, 35 or -NR2COOR5, where R2, R3, R+, and R5 may be the same or different and may be hydrogen, all preferably of from 1 to 10 carbons, more preferably from 1 to 6 carbon atoms, alkoxyalkyl, wherein the all groups may be the same or different and preferably contain from 1 to 10 carbon atoms, more preferably from 1 to 6 carbon atoms, alkoxyaryl, wherein the all groups contain from 1 to about 6 atoms, cycloalkyl, preferably of from 3 to 8 carbon atoms, alkenyl, preferably of from 3 to 10 carbon atoms, alkynyl, preferably 40 of from 3 to 10 carbon atoms, aryl, which may be selected from substituted and unsubstituted monocyclic and polycyclic aromatic and heterocyclic ring systems of from 6 to about 10 carbon atoms such as phenyl, thienyl, imidazole and oxazole, indole, heteroaryl, or aralkyl, except that R3 and R+ may together with N form a 5-to 7-membered heterocyclic group. A specific embodiment of the invention involves the utilization of an HBr/acetic acid (AcOH) mixture to 45 directly convert the ketal (3) to the bromoacetozy (5) without going through the intermediate diol (4). The bromoacetoxy (5) is then allowed to react with a selected amine in an alcoholic medium to provide the desired aryloxypropanolamine. An alternative procedure for the latter reaction is to convert the bromacetoxy (5) to an epoxide followed by amination. The method offers the convenience of fewer reaction steps. More generally, a mixture of a strong acid, HX, where X is chloro, bormo or iodo, in an amount of from 0.1 to 50 50% in an organic acid, Y-COOH where Y is hydrogen, loweralkyl or cycloalkyl, is used to convert the ketal (3). DETAILED DESCRIPTION OF THE INVENTION 55 As used herein, the term "aryl" may represent a phenyl or naphthyl group which may be unsubstituted or substituted with alkyl of from 1 to about 6 carbon atoms, alkenyl of from 2 to about 6 carbon atoms, alkynyl of from 2 to about 10 carbon atoms, alkoxy wherein the alkyl group contains from 1 to about 6 carbon atoms, halo, acetamido, amino, amido, nitro, alkylamino of from 1 to about 6 carbon atoms, hydroxy, EP 0 249 610 B1 hydroxyalkyl of from 1 to about 6 carbon atoms, cyano or arylalkoxy wherein the alkyl group contains from 1 to about 6 carbon atoms and the aryl group is substituted or unsubstituted phenyl. The term "heteroaryl" as used herein may represent pyridine, pyrazine, pyrrole, pyrazole, piperazine, thiophene, benzothiophene, furan, benzofuran, imidazole, oxazole, indole, carbazole, thiazole, thiadiazole, 5 benzothiadiazole, triazole, tetrazole, azepine, 1, 2-diazepine, or 1 ,4-thiazepine. Preferably, the heteroaryl is selected from the group consisting of pyridine, pyrazine, thiophene, benzothiophene, benzofuran, indole, carbazole, thiadiazole or benzothiadiazole, with the most preferred being pyrazine, indole, 1 ,2,5-thiadiazole, or benzofuran. The term "heterocyclic" as used herein may represent pyrrolidine, piperidine, morpholine, or thiomor- io pholine. In the term "aralkyl" as used herein, the alkyl group may contain from about 1 to about 6 carbon atoms and the aryl group may represent substituted or unsubstituted monocyclic or polycyclic aromatic or heterocyclic ring systems of from 5 to 10 carbon atoms, such as benzyl, phenethyl, 3,4-dimethoxyphenethyl and 1 ,1-dimethyl-2-(3-indolyl)-ethyl Aromatic (Ar) substituents may include lower alkyl of from 1 to 10 is carbons atoms, alkenyl of from 2 to 10 carbon atoms, alkynyl of from 2 to 10 carbon atoms, alkoxy wherein the alkyl group contains from 1 to 10 carbon atoms, halo, acetamido, amino, nitro, alkylamino of from 1 to 10 carbon atoms, hydroxy, hydroxyalkyl of from 1 to 10 carbon atoms, cyano, arylalkoxy wherein the alkyl group contains from 1 to 6 carbon atoms and the aryl group represents substituted or unsubstituted phenyl and groups of the formula 20 O a Ry-O- C- A 25 wherein R3 is lower alkyl, aryl or aralkyl and A is a direct bond, alkylene of from 1 to 10 carbon atoms or alkenylene of from 2 to 10 carbon atoms. The term "cycloalkyl" as used herein refers to cyclic saturated aliphatic radicals, which may contain 3 30 to 6 carbon atoms in the ring, such as cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl. R3 and R4 may together with N form a 5- to 7-membered heterocyclic group such as pyrrolidine, piperidine, piperazine morpholine, or thiomorpholine.
Recommended publications
  • (12) United States Patent (10) Patent No.: US 9,498,481 B2 Rao Et Al
    USOO9498481 B2 (12) United States Patent (10) Patent No.: US 9,498,481 B2 Rao et al. (45) Date of Patent: *Nov. 22, 2016 (54) CYCLOPROPYL MODULATORS OF P2Y12 WO WO95/26325 10, 1995 RECEPTOR WO WO99/O5142 2, 1999 WO WOOO/34283 6, 2000 WO WO O1/92262 12/2001 (71) Applicant: Apharaceuticals. Inc., La WO WO O1/922.63 12/2001 olla, CA (US) WO WO 2011/O17108 2, 2011 (72) Inventors: Tadimeti Rao, San Diego, CA (US); Chengzhi Zhang, San Diego, CA (US) OTHER PUBLICATIONS Drugs of the Future 32(10), 845-853 (2007).* (73) Assignee: Auspex Pharmaceuticals, Inc., LaJolla, Tantry et al. in Expert Opin. Invest. Drugs (2007) 16(2):225-229.* CA (US) Wallentin et al. in the New England Journal of Medicine, 361 (11), 1045-1057 (2009).* (*) Notice: Subject to any disclaimer, the term of this Husted et al. in The European Heart Journal 27, 1038-1047 (2006).* patent is extended or adjusted under 35 Auspex in www.businesswire.com/news/home/20081023005201/ U.S.C. 154(b) by Od en/Auspex-Pharmaceuticals-Announces-Positive-Results-Clinical M YW- (b) by ayS. Study (published: Oct. 23, 2008).* This patent is Subject to a terminal dis- Concert In www.concertpharma. com/news/ claimer ConcertPresentsPreclinicalResultsNAMS.htm (published: Sep. 25. 2008).* Concert2 in Expert Rev. Anti Infect. Ther. 6(6), 782 (2008).* (21) Appl. No.: 14/977,056 Springthorpe et al. in Bioorganic & Medicinal Chemistry Letters 17. 6013-6018 (2007).* (22) Filed: Dec. 21, 2015 Leis et al. in Current Organic Chemistry 2, 131-144 (1998).* Angiolillo et al., Pharmacology of emerging novel platelet inhibi (65) Prior Publication Data tors, American Heart Journal, 2008, 156(2) Supp.
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2006/0110428A1 De Juan Et Al
    US 200601 10428A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2006/0110428A1 de Juan et al. (43) Pub. Date: May 25, 2006 (54) METHODS AND DEVICES FOR THE Publication Classification TREATMENT OF OCULAR CONDITIONS (51) Int. Cl. (76) Inventors: Eugene de Juan, LaCanada, CA (US); A6F 2/00 (2006.01) Signe E. Varner, Los Angeles, CA (52) U.S. Cl. .............................................................. 424/427 (US); Laurie R. Lawin, New Brighton, MN (US) (57) ABSTRACT Correspondence Address: Featured is a method for instilling one or more bioactive SCOTT PRIBNOW agents into ocular tissue within an eye of a patient for the Kagan Binder, PLLC treatment of an ocular condition, the method comprising Suite 200 concurrently using at least two of the following bioactive 221 Main Street North agent delivery methods (A)-(C): Stillwater, MN 55082 (US) (A) implanting a Sustained release delivery device com (21) Appl. No.: 11/175,850 prising one or more bioactive agents in a posterior region of the eye so that it delivers the one or more (22) Filed: Jul. 5, 2005 bioactive agents into the vitreous humor of the eye; (B) instilling (e.g., injecting or implanting) one or more Related U.S. Application Data bioactive agents Subretinally; and (60) Provisional application No. 60/585,236, filed on Jul. (C) instilling (e.g., injecting or delivering by ocular ion 2, 2004. Provisional application No. 60/669,701, filed tophoresis) one or more bioactive agents into the Vit on Apr. 8, 2005. reous humor of the eye. Patent Application Publication May 25, 2006 Sheet 1 of 22 US 2006/0110428A1 R 2 2 C.6 Fig.
    [Show full text]
  • Customs Tariff - Schedule
    CUSTOMS TARIFF - SCHEDULE 99 - i Chapter 99 SPECIAL CLASSIFICATION PROVISIONS - COMMERCIAL Notes. 1. The provisions of this Chapter are not subject to the rule of specificity in General Interpretative Rule 3 (a). 2. Goods which may be classified under the provisions of Chapter 99, if also eligible for classification under the provisions of Chapter 98, shall be classified in Chapter 98. 3. Goods may be classified under a tariff item in this Chapter and be entitled to the Most-Favoured-Nation Tariff or a preferential tariff rate of customs duty under this Chapter that applies to those goods according to the tariff treatment applicable to their country of origin only after classification under a tariff item in Chapters 1 to 97 has been determined and the conditions of any Chapter 99 provision and any applicable regulations or orders in relation thereto have been met. 4. The words and expressions used in this Chapter have the same meaning as in Chapters 1 to 97. Issued January 1, 2020 99 - 1 CUSTOMS TARIFF - SCHEDULE Tariff Unit of MFN Applicable SS Description of Goods Item Meas. Tariff Preferential Tariffs 9901.00.00 Articles and materials for use in the manufacture or repair of the Free CCCT, LDCT, GPT, UST, following to be employed in commercial fishing or the commercial MT, MUST, CIAT, CT, harvesting of marine plants: CRT, IT, NT, SLT, PT, COLT, JT, PAT, HNT, Artificial bait; KRT, CEUT, UAT, CPTPT: Free Carapace measures; Cordage, fishing lines (including marlines), rope and twine, of a circumference not exceeding 38 mm; Devices for keeping nets open; Fish hooks; Fishing nets and netting; Jiggers; Line floats; Lobster traps; Lures; Marker buoys of any material excluding wood; Net floats; Scallop drag nets; Spat collectors and collector holders; Swivels.
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 6,264,917 B1 Klaveness Et Al
    USOO6264,917B1 (12) United States Patent (10) Patent No.: US 6,264,917 B1 Klaveness et al. (45) Date of Patent: Jul. 24, 2001 (54) TARGETED ULTRASOUND CONTRAST 5,733,572 3/1998 Unger et al.. AGENTS 5,780,010 7/1998 Lanza et al. 5,846,517 12/1998 Unger .................................. 424/9.52 (75) Inventors: Jo Klaveness; Pál Rongved; Dagfinn 5,849,727 12/1998 Porter et al. ......................... 514/156 Lovhaug, all of Oslo (NO) 5,910,300 6/1999 Tournier et al. .................... 424/9.34 FOREIGN PATENT DOCUMENTS (73) Assignee: Nycomed Imaging AS, Oslo (NO) 2 145 SOS 4/1994 (CA). (*) Notice: Subject to any disclaimer, the term of this 19 626 530 1/1998 (DE). patent is extended or adjusted under 35 O 727 225 8/1996 (EP). U.S.C. 154(b) by 0 days. WO91/15244 10/1991 (WO). WO 93/20802 10/1993 (WO). WO 94/07539 4/1994 (WO). (21) Appl. No.: 08/958,993 WO 94/28873 12/1994 (WO). WO 94/28874 12/1994 (WO). (22) Filed: Oct. 28, 1997 WO95/03356 2/1995 (WO). WO95/03357 2/1995 (WO). Related U.S. Application Data WO95/07072 3/1995 (WO). (60) Provisional application No. 60/049.264, filed on Jun. 7, WO95/15118 6/1995 (WO). 1997, provisional application No. 60/049,265, filed on Jun. WO 96/39149 12/1996 (WO). 7, 1997, and provisional application No. 60/049.268, filed WO 96/40277 12/1996 (WO). on Jun. 7, 1997. WO 96/40285 12/1996 (WO). (30) Foreign Application Priority Data WO 96/41647 12/1996 (WO).
    [Show full text]
  • Tetrapeptide Renin Inhibitors Having a Novel C-Terminal Amino Acid
    Europaisches Patentamt 0 312 157 European Patent Office © Publication number: A2 Office europeen des brevets EUROPEAN PATENT APPLICATION A61K 37/64 © Application number:. 8820221 0.6 © int. CI.4: C07K 5/02 , © Date of filing: 05.10.88 §) Priority: 13.10.87 US 107212 © Applicant: MERCK & CO. INC. 126, East Lincoln Avenue P.O. Box 2000 © Date of publication of application: Rahway New Jersey 07065-0900(US) 19.04.89 Bulletin 89/16 © Inventor: Chakravarty, Prasun K. © Designated Contracting States: 16 Churchill Road CH DE FR GB IT LI NL Edison New Jersey 08820(US) Inventor: Greenlee, William J. 115 Herrick Avenue Teaneck New Jersey 07666(US) Inventor: Parsons, William H. 2171 Oliver Street Rahway New Jersey 07065(US) Inventor: Schoen, William 196 White Birch Road Edison New Jersey 08837(US) © Representative: Hesketh, Alan, Dr. European Patent Department Merck & Co., Inc. Teriings Park Eastwick Road Harlow Essex, CM20 2QR(GB) © Tetrapeptide renin inhibitors having a novel c-terminal amino acid. © Tetrapeptide enzyme inhibitors of the formula: A-N A N c JM is CM •10b It II 0 0 < r ^2 CM and analogs thereof which inhibit renin and are useful for treating various forms of renin-associatea hypertension, hyperaldosteronism and congestive heart failure; compositions containing these renin-inhibi- CO tory peptides, optionally with other antihypertensive agents; and methods of treating hypertension, hyperal- dosteronism or congestive heart failure or of establishing renin as a causative factor in these problems Q. employing the novel tetrapeptides.
    [Show full text]
  • Ovid MEDLINE(R)
    Supplementary material BMJ Open Ovid MEDLINE(R) and Epub Ahead of Print, In-Process & Other Non-Indexed Citations and Daily <1946 to September 16, 2019> # Searches Results 1 exp Hypertension/ 247434 2 hypertens*.tw,kf. 420857 3 ((high* or elevat* or greater* or control*) adj4 (blood or systolic or diastolic) adj4 68657 pressure*).tw,kf. 4 1 or 2 or 3 501365 5 Sex Characteristics/ 52287 6 Sex/ 7632 7 Sex ratio/ 9049 8 Sex Factors/ 254781 9 ((sex* or gender* or man or men or male* or woman or women or female*) adj3 336361 (difference* or different or characteristic* or ratio* or factor* or imbalanc* or issue* or specific* or disparit* or dependen* or dimorphism* or gap or gaps or influenc* or discrepan* or distribut* or composition*)).tw,kf. 10 or/5-9 559186 11 4 and 10 24653 12 exp Antihypertensive Agents/ 254343 13 (antihypertensiv* or anti-hypertensiv* or ((anti?hyperten* or anti-hyperten*) adj5 52111 (therap* or treat* or effective*))).tw,kf. 14 Calcium Channel Blockers/ 36287 15 (calcium adj2 (channel* or exogenous*) adj2 (block* or inhibitor* or 20534 antagonist*)).tw,kf. 16 (agatoxin or amlodipine or anipamil or aranidipine or atagabalin or azelnidipine or 86627 azidodiltiazem or azidopamil or azidopine or belfosdil or benidipine or bepridil or brinazarone or calciseptine or caroverine or cilnidipine or clentiazem or clevidipine or columbianadin or conotoxin or cronidipine or darodipine or deacetyl n nordiltiazem or deacetyl n o dinordiltiazem or deacetyl o nordiltiazem or deacetyldiltiazem or dealkylnorverapamil or dealkylverapamil
    [Show full text]
  • C-Terminal Amide Cyclic Renin Inhibitors Containing Peptide Isosteres
    Europaisches Patentamt (191 European Patent Office (2) Publication number 0 156 318 Office europeen des brevets A2 EUROPEAN PATENT APPLICATION © Application number: 85103362.1 © Int CI 4: C 07 K 7/06 C 07 K 5/00, C 07 K 5/12 @ Date of filing- 22.03.85 A 61 K 37/02 @ Priority 27.03.84 US 593753 0 Applicant MERCK & CO INC. 126. East Lincoln Avenue P.O. Box 2000 Rahway New Jersey 07065IUS) @ Date o< publication of application: 02 10 85 Bulletin 85 40 @ Inventor Boger. Joshua S Arnecliffe Lodge 719 New Gulph Road @ Designated Contracting States Bryn Mawr Pennsylvania 19010(US) CH DE FR GB IT LI NL @ Representative: Abitz, Walter, Dr.-lng. et al, Abitz, Morf, Gritschneder, Frelherr von Wittgenstein Postfach 86 01 09 D-8000 Munchen 86IDE) @ C-terminal amide cyclic renin inhibitors containing peptide isosteres. Renin inhibitory peptides of the formula and analogs thereof inhibit renin and are useful for treating various forms of renin-associated hypertension and hyperal- dosteronism. BACKGROUND OF THE INVENTION 1. Field of The Invention The present invention is concerned with novel peptides which inhibit renin. The present invention is also concerned with pharmaceutical compositions containing the novel peptides of the present invention as active ingredi- ents. with methods of treating renin-associated hypertension and hyperaldosteronism, with diagnostic methods which utilize the novel peptides of the present invention, and with methods of preparing the novel peptides of the present invention. Renin is a proteolytic enzyme of molecular weight about 40,000, produced and secreted by the kidney. It is secreted by the juxtaglomerular cells and acts on the plasma substrate, angiotensinogen, to split off the decapeptide angiotensin I, which is converted to the potent pressor agent angiotensin II.
    [Show full text]
  • The Interrelation of Physicochemical Parameters and Topological Descriptors for a Series of Â-Blocking Agents
    976 J. Chem. Inf. Comput. Sci. 2002, 42, 976-982 The Interrelation of Physicochemical Parameters and Topological Descriptors for a Series of â-Blocking Agents John M. Quigley* and Sarah M. Naughton Department of Pharmaceutical Chemistry, Trinity College, Dublin 2, Ireland Received March 20, 2002 The intercorrelation between a series of physicochemical parameters and topological indices for a set of â-blockers is investigated. Partition coefficients are calculated using the ClogP program, and the results are compared with previous data, both experimental and theoretical. These data are complemented by hydrophilicity and solubility calculations, together with the determination of molecular area and volume. Connectivity indices, of order 1 and 2, including simple, valence, and differential terms, are evaluated. The derivation of a recently proposed topological descriptor, the eccentric adjacency index, from the adjacency and distance matrices, is presented. The corresponding valence term, a novel descriptor, is developed, and other indices related to the distance matrix, the Wiener and Hyper-Wiener terms, are included. A high degree of linear correlation between the connectivity indices is noted. The correlations for first-order terms are slightly superior to the corresponding second-order values. This is particularly true when considering the valence terms compared with the nonvalence terms. The relationship between these terms and reported pharmacological properties are investigated. A decrease in the eccentric adjacency index resulted
    [Show full text]
  • Renin Inhibitory Peptides Containing Suleptanic Acid Or Derivatives Thereof
    Europaisches Patentamt i) European Patent Office Publication number: 0 355 065 Office europeen des brevets A1 EUROPEAN PATENT APPLICATION Application number: 89308393.1 Intel.": C 07 K 5/02 A 61 K 37/64 Date of filing: 18.08.89 Priority: 19.08.88 US 234413 ® Applicant: THE UPJOHN COMPANY 20.07.89 PC /US89/03093 301 Henrietta Street Kalamazoo, Michigan 49001 (US) Date of publication of application: 21.02.90 Bulletin 90/08 @ Inventor: Thaisrivongs, Suvit 1327 Edington Avenue Designated Contracting States: Portage Michigan 49002 (US) AT BE CH DE ES FR GB GR IT LI LU NL SE @ Representative : Perry, Robert Edward et al GILL JENNINGS & EVERY 53-64 Chancery Lane London WC2A1HN (GB) @ Renin inhibitory peptides containing suleptanic acid or derivatives thereof. @ The present invention provides novel renin-inhibiting peptides having a non-cleavable transition state insert corre- sponding to the 10,11- position of the renin substrate (angiotensinogen) and having a suleptanic acid moiety or derivatives thereof of the formula Li at the N-terminus of the peptide. Such inhibitors are useful for the diagnosis and control of renin-dependent hypertension, congestive heart failure, renin dependent hyperaldosterism, other renin dependent cardiovas- cular disorders and ocular disorders. 0 0 II Y103S-(CH2)n-N(R1)-C-(CH2)q-C- Lx 8 8 CO 0L LU Bundesdruckerei Berlin EP 0 355 065 A1 Description RENIN INHIBITORY PEPTIDES CONTAINING SULEPTANIC ACID OR DERIVATIVES THEREOF 5 BACKGROUND OF THE INVENTION The present invention provides novel compounds. More particularly, the present invention provides novel renin-inhibiting peptide analogs. Most particularly, the present invention provides renin-inhibitory peptides containing a non-cleavable transition state insert corresponding to the 10,11-position of the renin substrate 10 (angiotensinogen) and containing a suleptanic acid moiety H03S(CH2)2-N(CH3)C0(CH2)6C02H or derivatives thereof at the N-terminus of the peptide.
    [Show full text]
  • Drugs for Primary Prevention of Atherosclerotic Cardiovascular Disease: an Overview of Systematic Reviews
    Supplementary Online Content Karmali KN, Lloyd-Jones DM, Berendsen MA, et al. Drugs for primary prevention of atherosclerotic cardiovascular disease: an overview of systematic reviews. JAMA Cardiol. Published online April 27, 2016. doi:10.1001/jamacardio.2016.0218. eAppendix 1. Search Documentation Details eAppendix 2. Background, Methods, and Results of Systematic Review of Combination Drug Therapy to Evaluate for Potential Interaction of Effects eAppendix 3. PRISMA Flow Charts for Each Drug Class and Detailed Systematic Review Characteristics and Summary of Included Systematic Reviews and Meta-analyses eAppendix 4. List of Excluded Studies and Reasons for Exclusion This supplementary material has been provided by the authors to give readers additional information about their work. © 2016 American Medical Association. All rights reserved. 1 Downloaded From: https://jamanetwork.com/ on 09/28/2021 eAppendix 1. Search Documentation Details. Database Organizing body Purpose Pros Cons Cochrane Cochrane Library in Database of all available -Curated by the Cochrane -Content is limited to Database of the United Kingdom systematic reviews and Collaboration reviews completed Systematic (UK) protocols published by by the Cochrane Reviews the Cochrane -Only systematic reviews Collaboration Collaboration and systematic review protocols Database of National Health Collection of structured -Curated by Centre for -Only provides Abstracts of Services (NHS) abstracts and Reviews and Dissemination structured abstracts Reviews of Centre for Reviews bibliographic
    [Show full text]
  • Marrakesh Agreement Establishing the World Trade Organization
    No. 31874 Multilateral Marrakesh Agreement establishing the World Trade Organ ization (with final act, annexes and protocol). Concluded at Marrakesh on 15 April 1994 Authentic texts: English, French and Spanish. Registered by the Director-General of the World Trade Organization, acting on behalf of the Parties, on 1 June 1995. Multilat ral Accord de Marrakech instituant l©Organisation mondiale du commerce (avec acte final, annexes et protocole). Conclu Marrakech le 15 avril 1994 Textes authentiques : anglais, français et espagnol. Enregistré par le Directeur général de l'Organisation mondiale du com merce, agissant au nom des Parties, le 1er juin 1995. Vol. 1867, 1-31874 4_________United Nations — Treaty Series • Nations Unies — Recueil des Traités 1995 Table of contents Table des matières Indice [Volume 1867] FINAL ACT EMBODYING THE RESULTS OF THE URUGUAY ROUND OF MULTILATERAL TRADE NEGOTIATIONS ACTE FINAL REPRENANT LES RESULTATS DES NEGOCIATIONS COMMERCIALES MULTILATERALES DU CYCLE D©URUGUAY ACTA FINAL EN QUE SE INCORPOR N LOS RESULTADOS DE LA RONDA URUGUAY DE NEGOCIACIONES COMERCIALES MULTILATERALES SIGNATURES - SIGNATURES - FIRMAS MINISTERIAL DECISIONS, DECLARATIONS AND UNDERSTANDING DECISIONS, DECLARATIONS ET MEMORANDUM D©ACCORD MINISTERIELS DECISIONES, DECLARACIONES Y ENTEND MIENTO MINISTERIALES MARRAKESH AGREEMENT ESTABLISHING THE WORLD TRADE ORGANIZATION ACCORD DE MARRAKECH INSTITUANT L©ORGANISATION MONDIALE DU COMMERCE ACUERDO DE MARRAKECH POR EL QUE SE ESTABLECE LA ORGANIZACI N MUND1AL DEL COMERCIO ANNEX 1 ANNEXE 1 ANEXO 1 ANNEX
    [Show full text]
  • Self-Measured Compared to Office
    Systematic Review for the 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: Supplemental Tables and Figures Part 1: Self-Measured Compared to Office-Based Measurement of Blood Pressure in the Management of Adults With Hypertension Table 1.1 Electronic search terms used for the current meta-analysis (Part 1 – Self-Measured Compared to Office-Based Measurement of Blood Pressure in the Management of Adults With Hypertension). PubMed Search (Blood Pressure Monitoring, Ambulatory [mesh] OR self care [mesh] OR telemedicine [mesh] OR patient participation [tiab] OR ambulatory [tiab] OR kiosk [tiab] OR kiosks [tiab] OR self-monitor* [tiab] OR self-measure* [tiab] OR self-care* [tiab] OR self-report* [tiab] OR telemonitor* [tiab] OR tele-monitor* [tiab] OR home monitor* [tiab] OR telehealth [tiab] OR tele-health [tiab] OR telemonitor* [tiab] OR tele-monitor* [tiab] OR telemedicine [tiab] OR patient-directed [tiab] OR Blood pressure monitoring “patient directed” [tiab] OR HMBP [tiab] OR SMBP [tiab] OR home [tiab] OR white coat [tiab] OR concept + Self Care concept ((patient participation [ot] OR ambulatory [ot] OR kiosk [ot] OR kiosks [ot] OR self-monitor* [ot] OR self-measure* [ot] OR self-care* [ot] OR self-report* [ot] OR telemonitor* [ot] OR tele-monitor* [ot] OR home monitor* [ot] OR telehealth [ot] OR tele-health [ot] OR telemonitor* [ot] OR tele- monitor* [ot] OR telemedicine [ot] OR patient-directed [tiab] OR “patient directed” [tiab]
    [Show full text]